866-997-4948(US-Canada Toll Free)

Alpha-Antitrypsin Deficiency-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Aug 2017

Category :

Pharmaceutical

No. of Pages : 83 Pages

Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017, provides an overview of the Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline landscape.

Alpha-antitrypsin deficiency is an inherited disease that occurs due to lack of alpha-1 antitrypsin (AAT), a protein that protects the lungs. Symptoms include shortness of breath and wheezing, lung infections, rapid heartbeat, weight loss and vision problems. Predisposing factors include smoking, exposure to dust, chemical fumes and infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alpha- Antitrypsin Deficiency - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Alpha- Antitrypsin Deficiency (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Alpha- Antitrypsin Deficiency and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 2, 9 and 5 respectively. Similarly, the Universities portfolio in Discovery stages comprises 1 molecules, respectively.

Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alpha- Antitrypsin Deficiency (Genetic Disorders).
- The pipeline guide reviews pipeline therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alpha- Antitrypsin Deficiency (Genetic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alpha- Antitrypsin Deficiency (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alpha- Antitrypsin Deficiency (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alpha- Antitrypsin Deficiency (Genetic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alpha- Antitrypsin Deficiency (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Alpha- Antitrypsin Deficiency - Overview 6
Alpha- Antitrypsin Deficiency - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 13
Alpha- Antitrypsin Deficiency - Therapeutics Assessment 14
Assessment by Target 14
Assessment by Mechanism of Action 16
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Alpha- Antitrypsin Deficiency - Companies Involved in Therapeutics Development 22
Adverum Biotechnologies Inc 22
Alnylam Pharmaceuticals Inc 22
Applied Genetic Technologies Corp 23
Arrowhead Pharmaceuticals Inc 23
Carolus Therapeutics Inc 24
Cevec Pharmaceuticals GmbH 24
Editas Medicine Inc 25
Grifols SA 25
Inhibrx LP 26
Intellia Therapeutics Inc 26
International Stem Cell Corp 27
Kamada Ltd 27
OncBioMune Pharmaceuticals Inc 28
Polyphor Ltd 28
ProMetic Life Sciences Inc 29
rEVO Biologics Inc 29
Z Factor Ltd 30
Alpha- Antitrypsin Deficiency - Drug Profiles 31
ADVM-043 - Drug Profile 31
AGTC-0106 - Drug Profile 33
ALN-AAT - Drug Profile 35
ALNAAT-02 - Drug Profile 38
alpha-1 proteinase inhibitor (human) - Drug Profile 39
alpha-1 proteinase inhibitor (human) second generation - Drug Profile 40
alpha-1 proteinase inhibitor (recombinant) - Drug Profile 44
ARC-AAT - Drug Profile 46
ARO-AAT - Drug Profile 50
CT-2009 - Drug Profile 51
Drug for Chronic Obstructive Pulmonary Disease and Alpha-1 Antitrypsin Deficiency - Drug Profile 52
Gene Therapy for Alpha-1 Antitrypsin Deficiency - Drug Profile 53
Oligonucleotides to Activate Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - Drug Profile 54
Oligonucleotides to Inhibit Alpha-1 Antitrypsin for Alpha-Antitrypsin Deficiency - Drug Profile 55
POL-6014 - Drug Profile 56
rAAV2-CB-hAAT - Drug Profile 58
Recombinant Human Alpha-1 Antitrypsin - Drug Profile 59
Recombinant Human Alpha-1 Antitrypsin Replacement for Alpha-Antitrypsin Deficiency - Drug Profile 60
Recombinant Protein for Alpha-1 Antitrypsin Deficiency - Drug Profile 61
Small Molecules for Alpha-1 Antitrypsin Deficiency - Drug Profile 62
Small Molecules to Activate SERPINA1 for Alpha-1 Antitrypsin Deficiency - Drug Profile 63
Small Molecules to Inhibit Alpha-1 Antitrypsin Polymerization for Alpha-1 Antitrypsin Deficiency - Drug Profile 64
Stem Cell Therapy for Alpha-Antitrypsin Deficiency, Crigler-Najjar Syndrome and Liver Cirrhosis - Drug Profile 65
Alpha- Antitrypsin Deficiency - Dormant Projects 66
Alpha- Antitrypsin Deficiency - Discontinued Products 67
Alpha- Antitrypsin Deficiency - Product Development Milestones 68
Featured News & Press Releases 68
Appendix 80
Methodology 80
Coverage 80
Secondary Research 80
Primary Research 80
Expert Panel Validation 80
Contact Us 80
Disclaimer 81

List of Tables
Number of Products under Development for Alpha- Antitrypsin Deficiency, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by Adverum Biotechnologies Inc, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by Alnylam Pharmaceuticals Inc, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by Applied Genetic Technologies Corp, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by Carolus Therapeutics Inc, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by Cevec Pharmaceuticals GmbH, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by Editas Medicine Inc, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by Grifols SA, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by Inhibrx LP, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by Intellia Therapeutics Inc, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by International Stem Cell Corp, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by Kamada Ltd, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by OncBioMune Pharmaceuticals Inc, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by Polyphor Ltd, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by ProMetic Life Sciences Inc, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by rEVO Biologics Inc, H2 2017
Alpha- Antitrypsin Deficiency - Pipeline by Z Factor Ltd, H2 2017
Alpha- Antitrypsin Deficiency - Dormant Projects, H2 2017
Alpha- Antitrypsin Deficiency - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Alpha- Antitrypsin Deficiency, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *